Vertex Second Phase II Study Supports Telaprevir 24-Week Regimen
This article was originally published in The Pink Sheet Daily
Executive Summary
Adverse events associated with the hep C treatment are “troublesome,” not “troubling,” Vertex CEO Boger says.
You may also be interested in...
Telaprevir Phase IIb Data Continues To Support 24-Week Dosing For Hepatitis C, Vertex Says
PROVE-2 data show 65 percent sustained viral response in treatment naive patients, Vertex reports.
Telaprevir Phase IIb Data Continues To Support 24-Week Dosing For Hepatitis C, Vertex Says
PROVE-2 data show 65 percent sustained viral response in treatment naive patients, Vertex reports.
Human Genome Sciences Achieves Milestone For Albuferon Phase II Completion
HGS expects data from ACHIEVE pivotal program by spring 2009; global filings by fall 2009.